Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/7/2026

1. SPCX
2. CRNX
3. VRTX
4. WMT
5. LMT
6. RXST
7. SPGI
8. RIVN
9. AGIO
10. SPY

Go back to Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics to develop obe-cel in adult Acute Lymphoblastic Leukemia (ALL) and advance broader platform

Autolus Therapeutics (AUTL) Deal with Blackstone Overall Positive - Mizuho

November 8, 2021 1:03 PM EST

Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $18.00 price target on Autolus Therapeutics (NASDAQ: AUTL) after catching up with management following today's Blackstone deal.

Goldstein notes the funding model is minimally dilutive to obe-cel's earning potential and the access to capital... More